Anti-viral guanosine-rich oligonucleotides
US6184369A · kind A · utility
13Cited by
10References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 23, 1995 |
| Grant date | Feb 6, 2001 |
| Priority date | — |
| Expiry date | Oct 23, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/3515
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The oligonucleotides have sufficient guanosine to form a guanosine tetrad and can be composed of at least about 40% guanosine nucleotides, the nucleotide sequence containing at least two runs of at least two guanosines. Some of the new oligonucleotides also contain phosphorothioate backbones and 3' end modifications. Representative guanosine-rich oligonucleotides of the present invention demonstrate anti-viral activity in tissue culture against HSV-2, HIV-1, HCMV and FMLV, and show specific inhibition of bacterial RNA polymerase enzymes T7 and T3, the FMLV and HIV-1 reverse transcriptase enzyme and eukaryotic RNA polymerase.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.